Advancing Tau PET Quantification in Alzheimer Disease with Machine Learning: Introducing THETA, a Novel Tau Summary Measure.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published Date:

Abstract

Alzheimer disease (AD) exhibits spatially heterogeneous 3- or 4-repeat tau deposition across participants. Our overall goal was to develop an automated method to quantify the heterogeneous burden of tau deposition into a single number that would be clinically useful. We used tau PET scans from 3 independent cohorts: the Mayo Clinic Study of Aging and Alzheimer's Disease Research Center (Mayo, = 1,290), the Alzheimer's Disease Neuroimaging Initiative (ADNI, = 831), and the Open Access Series of Imaging Studies (OASIS-3, = 430). A machine learning binary classification model was trained on Mayo data and validated on ADNI and OASIS-3 with the goal of predicting visual tau positivity (as determined by 3 raters following Food and Drug Administration criteria for F-flortaucipir). The machine learning model used region-specific SUV ratios scaled to cerebellar crus uptake. We estimated feature contributions based on an artificial intelligence-explainable method (Shapley additive explanations) and formulated a global tau summary measure, Tau Heterogeneity Evaluation in Alzheimer's Disease (THETA) score, using SUV ratios and Shapley additive explanations for each participant. We compared the performance of THETA with that of commonly used meta-regions of interest (ROIs) using the Mini-Mental State Examination, the Clinical Dementia Rating-Sum of Boxes, clinical diagnosis, and histopathologic staging. The model achieved a balanced accuracy of 95% on the Mayo test set and at least 87% on the validation sets. It classified tau-positive and -negative participants with an AUC of 1.00, 0.96, and 0.94 on the Mayo, ADNI, and OASIS-3 cohorts, respectively. Across all cohorts, THETA showed a better correlation with the Mini-Mental State Examination and the Clinical Dementia Rating-Sum of Boxes (ρ ≥ 0.45, < 0.05) than did meta-ROIs (ρ < 0.44, < 0.05) and discriminated between participants who were cognitively unimpaired and those who had mild cognitive impairment with an effect size of 10.09, compared with an effect size of 3.08 for meta-ROIs. Our proposed approach identifies positive tau PET scans and provides a quantitative summary measure, THETA, that effectively captures heterogeneous tau deposition observed in AD. The application of THETA for quantifying tau PET in AD exhibits great potential.

Authors

  • Robel K Gebre
    Department of Radiology, Mayo Clinic, Rochester, Minnesota.
  • Alexis Moscoso Rial
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Sheelakumari Raghavan
    Department of Radiology, Mayo Clinic, Rochester, Minnesota.
  • Heather J Wiste
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
  • Fiona Heeman
    Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Alejandro Costoya-Sánchez
    Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
  • Christopher G Schwarz
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, USA.
  • Anthony J Spychalla
    Department of Radiology, Mayo Clinic, Rochester, Minnesota.
  • Val J Lowe
    Department of Radiology, Mayo Clinic, Rochester, Minnesota.
  • Jonathan Graff-Radford
    Department of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA.
  • David S Knopman
    Department of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA.
  • Ronald C Petersen
    Department of Neurology, Mayo Clinic, Rochester, USA.
  • Michael Schöll
    Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden; Department of Psychiatry and Neurochemistry, Institute of Physiology and Neuroscience, University of Gothenburg, Gothenburg, Sweden; Dementia Research Centre, Institute of Neurology, University College London, London, UK; Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: michael.scholl@neuro.gu.se.
  • Melissa E Murray
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Clifford R Jack
    Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, USA.
  • Prashanthi Vemuri
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.